298 related articles for article (PubMed ID: 30964381)
1. Mucociliary Clearance in Former Tobacco Smokers with Both Chronic Obstructive Pulmonary Disease and Chronic Bronchitis and the Effect of Roflumilast.
Laube BL; Carson KA; Sharpless G; Paulin LM; Hansel NN
J Aerosol Med Pulm Drug Deliv; 2019 Aug; 32(4):189-199. PubMed ID: 30964381
[No Abstract] [Full Text] [Related]
2. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
Chong J; Leung B; Poole P
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD002309. PubMed ID: 28922692
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
Chong J; Leung B; Poole P
Cochrane Database Syst Rev; 2013 Nov; (11):CD002309. PubMed ID: 24190161
[TBL] [Abstract][Full Text] [Related]
5. Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial.
Rabe KF; Watz H; Baraldo S; Pedersen F; Biondini D; Bagul N; Hanauer G; Göhring UM; Purkayastha D; Román J; Alagappan VKT; Saetta M
Lancet Respir Med; 2018 Nov; 6(11):827-836. PubMed ID: 30224319
[TBL] [Abstract][Full Text] [Related]
6. Quantitative Assessment of Mucociliary Clearance in Smokers with Mild-to-Moderate Chronic Obstructive Pulmonary Disease and Chronic Bronchitis from Planar Radionuclide Imaging Using the Change in Penetration Index.
Fleming JS; Conway J; Bennett MJ; Tossici-Bolt L; Guy M; Blé FX; McCrae C; Carlsson M; Bondesson E
J Aerosol Med Pulm Drug Deliv; 2019 Aug; 32(4):175-188. PubMed ID: 30848685
[No Abstract] [Full Text] [Related]
7. Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.
Rennard SI; Calverley PM; Goehring UM; Bredenbröker D; Martinez FJ
Respir Res; 2011 Jan; 12(1):18. PubMed ID: 21272339
[TBL] [Abstract][Full Text] [Related]
8. Acute inhalation of hypertonic saline does not improve mucociliary clearance in all children with cystic fibrosis.
Laube BL; Sharpless G; Carson KA; Kelly A; Mogayzel PJ
BMC Pulm Med; 2011 Sep; 11():45. PubMed ID: 21896198
[TBL] [Abstract][Full Text] [Related]
9. Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD.
Hanania NA; Calverley PM; Dransfield MT; Karpel JP; Brose M; Zhu H; Goehring UM; Rowe P
Respir Med; 2014 Feb; 108(2):366-75. PubMed ID: 24120253
[TBL] [Abstract][Full Text] [Related]
10. [Novel trends in pharmacotherapy of chronic obstructive pulmonary disease--prevention of exacerbations (focus on roflumilast)].
Sinopal'nikov AI
Klin Med (Mosk); 2014; 92(2):57-64. PubMed ID: 25269184
[TBL] [Abstract][Full Text] [Related]
11. Roflumilast partially reverses smoke-induced mucociliary dysfunction.
Schmid A; Baumlin N; Ivonnet P; Dennis JS; Campos M; Krick S; Salathe M
Respir Res; 2015 Oct; 16():135. PubMed ID: 26521141
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of roflumilast as an add-on to triple inhaled therapy vs triple inhaled therapy in patients with severe and very severe COPD associated with chronic bronchitis in the UK.
Kiff C; Ruiz S; Varol N; Gibson D; Davies A; Purkayastha D
Int J Chron Obstruct Pulmon Dis; 2018; 13():2707-2720. PubMed ID: 30214188
[TBL] [Abstract][Full Text] [Related]
13. Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis.
Luo J; Wang K; Liu D; Liang BM; Liu CT
Respir Res; 2016 Feb; 17():18. PubMed ID: 26887407
[TBL] [Abstract][Full Text] [Related]
14. Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients.
Porpodis K; Domvri K; Zarogoulidis P; Petridis D; Tsirgogianni K; Papaioannou A; Hatzizisi O; Kioumis I; Liaka A; Kikidaki V; Lampaki S; Organtzis J; Zarogoulidis K
Int J Chron Obstruct Pulmon Dis; 2015; 10():1123-8. PubMed ID: 26109853
[TBL] [Abstract][Full Text] [Related]
15. A Randomized, Placebo-controlled Trial of Roflumilast. Effect on Proline-Glycine-Proline and Neutrophilic Inflammation in Chronic Obstructive Pulmonary Disease.
Wells JM; Jackson PL; Viera L; Bhatt SP; Gautney J; Handley G; King RW; Xu X; Gaggar A; Bailey WC; Dransfield MT; Blalock JE
Am J Respir Crit Care Med; 2015 Oct; 192(8):934-42. PubMed ID: 26151090
[TBL] [Abstract][Full Text] [Related]
16. Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis.
Lambert JA; Raju SV; Tang LP; McNicholas CM; Li Y; Courville CA; Farris RF; Coricor GE; Smoot LH; Mazur MM; Dransfield MT; Bolger GB; Rowe SM
Am J Respir Cell Mol Biol; 2014 Mar; 50(3):549-58. PubMed ID: 24106801
[TBL] [Abstract][Full Text] [Related]
17. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease.
Calverley PM; Sanchez-Toril F; McIvor A; Teichmann P; Bredenbroeker D; Fabbri LM
Am J Respir Crit Care Med; 2007 Jul; 176(2):154-61. PubMed ID: 17463412
[TBL] [Abstract][Full Text] [Related]
18. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
[TBL] [Abstract][Full Text] [Related]
19. Modeling and Simulation of Pivotal Clinical Trials Using Linked Models for Multiple Endpoints in Chronic Obstructive Pulmonary Disease With Roflumilast.
Facius A; Krause A; Claret L; Bruno R; Lahu G
J Clin Pharmacol; 2017 Aug; 57(8):1042-1052. PubMed ID: 28419462
[TBL] [Abstract][Full Text] [Related]
20. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.
Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Anzueto A; Alagappan VK; Siddiqui S; Rekeda L; Miller CJ; Zetterstrand S; Reisner C; Rennard SI
Am J Respir Crit Care Med; 2016 Sep; 194(5):559-67. PubMed ID: 27585384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]